Previous data suggest that developmental increases in peripheral concentrations of insulin-like growth factor-I (IGF-I) may be one of several neuroendocrine signals that regulate the timing of puberty. In order to test this hypothesis further, normal juvenile female rhesus monkeys (Con; n=6) were compared with age-matched animals (Igf; n=4) which received a constant subcutaneous infusion of recombinant human IGF-I (110 µg/kg/day) from 18 through 36 months of age. Menstrual bleeding was monitored and ovulation was inferred from a sustained rise in serum progesterone. In order to assess the sensitivity of luteinizing hormone-releasing hormone (LHRH) neurons to excitation, the response of serum LH to the acute administration of the glutamate receptor agonist N-methyl-, -aspartic acid (NMDA) was assessed prior to menarche, 2 months following menarche, and during the follicular phase of a female's third ovulation or 50 days after a female's first ovulation. In addition, the pituitary response of LH secretion to an LHRH agonist was assessed during the follicular phase of a female's fourth ovulation or 75 days following her first ovulation.
Introduction
Although the developmental pattern of luteinizing hormone releasing hormone (LHRH) and luteinizing hormone (LH) secretion is well documented (Terasawa et al. 1984 , Watanabe & Terasawa 1989 , the neuroendocrine mechanisms which re-establish pulsatile LHRH and, consequently, LH secretion during primate puberty are not fully understood. Following a brief neonatal activation of the hypothalamic-pituitary-ovarian axis (Plant 1986 ), a prolonged hypogonadotropic state ensues, characterized by low amplitude, infrequent pulses of LHRH and LH (Watanabe & Terasawa 1989 ). This hypogonadotropism may be the result of either an absence of stimulatory input to or an active inhibition of the LHRH neuronal system (see Terasawa 1995 for review) . However, it is clear that this juvenile condition is not due entirely to gonadal steroid negative feedback inhibition. Although ovariectomy during this phase results in a slight increase in nocturnal LHRH (Chongthammakun et al. 1993 ) and LH release (Pohl et al. 1995) , open loop secretion of these peptides (Terasawa et al. 1984 , Winter et al. 1987 gradually increases and only reaches agonadal, adult-like concentrations at an age when menarche would be expected (Wilson 1989) . Once LHRH and LH secretion is re-established, estradiol negative feedback inhibition becomes functionally important regulating further increases in these peptides. Indeed, the later stages of puberty in female primates is characterized by a decreasing sensitivity to estradiol negative feedback inhibition of LH secretion (Rapisarda et al. 1983 , Wilson 1995 such that the timing of this loss in hypersensitivity to estradiol negative feedback sets the tempo of puberty and determines the occurrence of first ovulation.
Recent evidence has suggested that signals from the growth process, specifically growth hormone (GH)-dependent increases in insulin-like growth factor-I (IGF-I), may facilitate developmental increases in LHRH and LH secretion during the final stages of puberty. In data derived from peri-pubertal rats, IGF-I stimulates the in vitro release of LHRH from the median eminence (Hiney et al. 1991) , and increases in serum IGF-I stimulate IGF receptor mRNA in the median eminence (Hiney et al. 1996) . Furthermore, the stimulation of LH release by the central administration of IGF-I is blocked by the immunoneutralization of LHRH in immature rats (Hiney et al. 1996) . In monkeys, the long-term administration of GH accelerates while the inhibition of endogenous GH and IGF-I release by a somatostatin analog delays (Wilson & Tanner 1994 ) the occurrence of first ovulation. However, neither treatment regimen affects age at menarche. Clinical observations indicate that GH deficiency is associated with delayed puberty (OgilvyStuart & Shalet 1992) and GH replacement accelerates the completion of puberty once it has begun (Darendelier et al. 1990 , Stanhope et al. 1992 . These data suggest that the importance of the GH axis in the development of LHRH and LH secretion in primates may be restricted to the later stages of puberty, specifically to changes in gonadal steroid negative feedback. Indeed, the long-term administration of IGF-I accelerates the loss of hypersensitivity to estradiol negative feedback inhibition of LH secretion in adolescent monkeys (Wilson 1995) . However, these data implicating a role for IGF-I in the development of LHRH secretion must be balanced against observations that IGF-I may inhibit LHRH-stimulated release from hypothalamic explants (Bourguinon et al. 1993) and that manipulations of endogenous IGF-I concentrations do not affect timing of vaginal opening in rats (Gruaz et al. 1994 (Gruaz et al. , 1997 .
In order to evaluate further the role of IGF-I in regulating developmental increases in LH secretion, juvenile female rhesus monkeys receiving a continuous subcutaneous infusion of IGF-I in order prematurely to elevate peripheral concentrations, were compared with age-matched controls. The working hypothesis was that a significant elevation in serum IGF-I concentrations would accelerate age at first ovulation and that this effect would be due to an augmentation of LH secretion and not necessarily to a change in ovarian responsiveness to gonadotropin stimulation induced by IGF-I (Giudice 1992) . To define further how IGF-I may affect the activity of LHRH neurons and pituitary responsiveness, the response of LH release to the acute administration of the glutamate receptor agonist N-methyl-, -aspartic acid (NMDA ; Brann 1995) and to an LHRH agonist were evaluated. The results of the study suggest that the premature elevation in peripheral IGF-I concentrations accelerates the occurrence of first ovulation by increasing the responsiveness of LHRH neurons and by an augmentation of LH secretion.
Materials and Methods

Subjects
Subjects were female rhesus monkeys (Macaca mulatta), born and raised at the Yerkes Primate Research Center of Emory University. Animals were socially housed indoors in large cages (4 per cage) under a 12 h light:12 h darkness cycle and a constant temperature range of 22-25 C as described previously (Wilson et al. 1988) . Animals were fed commercial monkey chow (Harlan Teklan Monkey Diet, Madison, WI, USA), available ad libitum, twice daily, fresh fruit once daily, and had continuous access to water. Food was given in sufficient quantity so that all animals could eat to satiety. The experimental protocol was approved by the Emory University Animal Care and Use Committee in compliance with all NIH and USDA Standards.
Procedures
Animals were studied from 18 months of age through their fourth ovulation or 36 months of age, whichever occurred first. Females were randomly assigned to a control group (Con; n=6) or to a treatment group (Igf; n=6) that received a constant, subcutaneous (s.c.) infusion of recombinant human (h) IGF-I (Genentech Inc., South San Francisco, CA, USA) at a dose of 110 µg/kg/day. These infusions were accomplished with Alzet osmotic mini-pumps (Alza Corp., Palo Alto, CA, USA) which were implanted s.c., under sterile conditions, between the scapula while the animals were under general anesthesia (Telazol; 4 mg/kg intramuscularly). The IGF-I was supplied pre-diluted in bacteriostatic water with benzyl alcohol as a preservative. Further dilutions were made with bacteriostatic water. Preparation of the pump followed the manufacture's directions. Using sterile techniques, the IGF-I solution was drawn into a calibrated 3 ml syringe. The pump reservoir averaged 2·18 0·04 ml. The pump was slowly filled with 2·2 ml solution until a small bead of solution appeared at the opening of the reservoir. After inserting the flow modulator into the pump, it was incubated in sterile saline at 24 C for 3 h before implantation.
Pumps were changed every 28 days or more frequently if needed. The dose used was chosen to elevate serum IGF-I approximately 100% compared with untreated, age-matched controls (Wilson 1995) . In order adequately to test the hypothesis that peripheral elevations of IGF-I levels advance maturation, the efficacy of the treatments was critical. Consequently, serum concentrations of IGF-I were determined periodically to ensure that levels were elevated to the desired range. As illustrated in Fig. 1 , this assessment revealed that two of the IGF-I-treated females consistently had serum IGF-I concentrations that were lower than the other IGF-treated females and, at later developmental ages, in the same range as the untreated, Con females. Serum IGF-binding protein-3 (IGFBP-3) concentrations were similarly reduced. Since this did not meet the criteria of the treatment, the data from these two Igf females were not included in the analysis. Indeed, the age at first ovulation for these two non-responding females was 32·8 0·9 months, similar to that of the Con females (see Results). Finally, the IGF-I-treated females were equally distributed throughout the 3 caging units (2 per cage) and the relative social ranks of the treated females, based on agonistic interactions, were as follows: cage 1: 2 and 4; cage 2: 1 and 2; cage 3: 3 and 4 (with 1 being the most socially dominant).
Blood samples were collected weekly through 20 months of age and twice weekly thereafter using procedures previously described (Wilson et al. 1988) . Samples were assayed for progesterone, estradiol, IGF-I, and IGFBP-3. Ovulation was inferred from an elevation (>3·18 nmol/l) of serum progesterone that was sustained for more than 10 days. Short luteal phase ovulations were inferred from serum progesterone values that were sustained for less than 10 days. Typically, these luteal phases are also characterized by diminished peak serum progesterone, and were defined as inadequate luteal phases. Short, inadequate luteal phases are typically associated with deficits in follicular maturation due to abnormal gonadotropin secretion (Wilks et al. 1979) . Animals were inspected daily for menstruation to document menarche and to assist in calculating the length of the luteal phase (rise in serum progesterone to menstruation). Each female was weighed monthly.
At three specific developmental periods: pre-menarche (20 months of age), 4 months post-menarche, and during either the peri-ovulatory phase of their third ovulation or 50 days after their first ovulation, a female's response to the glutamate receptor agonist NMDA was assessed. Repeated administration of NMDA elicits a sustained increase in LH in juvenile male monkeys (Gay & Plant 1987) . The acute administration of NMDA results in an increase in serum LH if the pituitary has been stimulated previously by LHRH; otherwise, little LH is released following NMDA (Gay & Plant 1987) . Thus, if IGF-I is having an effect on LHRH neurons, LH secretion should be enhanced in IGF-I-treated compared with untreated subjects following the acute administration of NMDA. At each assessment, females received 5 mg NMDA/kg intravenously (Sigma Chemical Corp., St Louis, MO, USA) at time 0 and again at +60 min following the first treatment. Blood samples were collected every 20 min for 60 min preceding and 120 min following the first NMDA treatment. Serum samples were assayed for LH. In addition, changes in serum LH following treatment with an LHRH analog (Lupron, leuprolide acetate; TAP Pharmaceuticals, Deerfield, IL, USA) was assessed to determine if IGF-I affected pituitary responsiveness to LHRH. During the follicular phase of her fourth ovulation or 75 days following her first ovulation, each female received a s.c. bolus injection of Lupron (14 µg/kg; Ibanez et al. 1994 ) and serum samples were collected at 24 h, 12 h, and just prior to treatment, and at 3, 6, 9, 12, 24, and 48 h following treatment and were assayed for LH.
Analyses
All samples were assayed in duplicate. Each assay contained samples from all females for a specified time period.
Figure 1
Individual distribution of serum IGF-I concentrations at three developmental stages for untreated, control females (Con) and females receiving a constant, s.c. infusion of IGF-I (Igf). The Igf females were further subdivided into those whose serum IGF-I levels were elevated () and those whose serum levels were not elevated (X) by the treatment.
Serum concentrations of estradiol and progesterone were determined by radioimmunoassay (RIA), using commercially available reagents (Diagnostic Products Corp., Los Angeles, CA, USA) as described previously (Wilson et al. 1988) . The estradiol assay used 200 µl serum and had a sensitivity of 5-7 pmol/tube (25 pmol/l) and an upper limit of 200 pmol/tube (1000 pmol/l). Intra-assay coefficients of variation were <4% while the interassay coefficient of variation at the midpoint of the standard curve was 12·5% 0·8 (n=50). For progesterone, 250 µl serum were extracted by 2 ml of an ether:hexane (9:1) system with the solvent layer evaporated under N 2 and reconstituted in assay diluent. Extraction efficiencies were calculated in every assay using the amount of 125 I-progesterone recovered (>95%). Sample concentrations were corrected by the extraction efficiency. The assay used 50 µl equivalents and had a sensitivity of 0·06 nmol/tube (1·2 nmol/l) and an upper limit of 12 nmol/tube (240 nmol/l). Intra-assay coefficients of variation were <4% while the interassay coefficient of variation at the midpoint of the standard curve was 11·5% 0·4 (n=62). Total serum concentrations of IGF-I were determined, following acid extraction of 100 µl serum, using an RIA validated for the monkey (Osterud et al. 1986 ). The assay used hIGF-I (Peninsula Labs, Belmont, CA, USA) as reference material and for iodination and a polyclonal anti-IGF-I antibody (National Hormone and Pituitary Program, NIDDK, USDA). Assuming a molecular mass of 7·5 kDa, concentrations of IGF-I were converted to nmol/l. The assay used 5 µl equivalents of reconstituted extract and had a sensitivity of 5 pmol/tube (1 nmol/l) and an upper limit of 1333 pmol/tube (266 nmol/l). Intra-assay coefficients of variation were <5% while the interassay coefficient of variation at the midpoint of the standard curve was 6·9% 0·4 (n=19). Concentrations of IGFBP-3 were measured by a commercially available immunoradiometric assay (Diagnostic Systems Laboratory, Webster, TX, USA). In order to minimize protein degradation and protease activity producing IGFBP-3 fragments, previously unthawed samples were assayed for IGFBP-3. Assuming a molecular mass of 27·5 kDa (reflecting the non-glycosylated form), concentrations of IGFBP-3 were converted to nmol/l. The assay used 5 µl serum and had a sensitivity of 3·3 pmol/tube (0·7 nmol/l) and an upper limit of 1750 pmol/tube (350 nmol/l). Intra-assay coefficients of variation were <5% while the interassay coefficient of variation was 20·3% 0·9 (n=7). Serum LH concentrations were determined by RIA which used recombinant monkey LH as the reference material and for iodination and a monoclonal antibody to monkey LH (Xiao et al. 1994 , National Hormone and Pituitary Program, NIDDK, USDA). The assay used 100-200 µl serum and had a sensitivity of 0·03 ng/tube (0·15-0·30 ng/ml) and an upper limit of 0·7 ng/tube (7-14 ng/ml). Intraassay coefficients of variation were <6% while the interassay coefficient of variation at the midpoint of the standard curve was 11·9% 0·9 (n=37).
Data are expressed as means ... for each group. Differences between Con and Igf groups over time were evaluated with a two-way analysis of variance for repeated measures (SPSS for the Macintosh; Chicago, IL, USA) with treatment (control vs IGF-I treated) as the main effect and advancing age or time as the repeated effect. Specific, post-hoc comparison's were made with the Fisher's LeastSquare Difference test. Differences between simple means (non-repeated, single measures) were evaluated with t-tests. Statistical tests that yielded a value of P<0·05 were considered to be significant. Given the small sample size (Con; n=6 and Igf; n=4), estimates of power were also calculated for specific statistical comparisons.
Results
Efficacy of IGF-I treatment
Continuous infusion with IGF-I elevated serum concentrations of IGF-I above those of Con females (Fig. 2, upper  panel) . Developmental increases were evident in serum IGF-I concentrations in Con females as well as Igf females (F 3,24 =34·22). Overall, the percentage increase in mean serum IGF-I for the Igf females was 86% ( 15) above the Con group. Group differences in serum concentrations of IGFBP-3 showed a similar pattern throughout the study period (Fig. 2, lower panel) . Although a developmental increase in serum IGFBP-3 was evident in all animals (F 3,24 =45·54), Igf females consistently had higher levels than Con females (F 1,8 =5·81). Serum IGFBP-3 was, on average, 25% ( 10) higher in Igf compared with Con females. The ratio of IGF-I to IGFBP-3 was also significantly higher in Igf compared with Con females throughout the course of the study ( Fig. 3; F 1,8 =35·12) . Interestingly, this ratio exhibited a significant developmental increase in Con but not in Igf females (F 3,24 =4·27). The ratio of IGF-I to IGFBP-3 remained relatively constant in Igf females throughout the course of the study.
Effects on maturation
Long-term administration of IGF-I did not advance the age at menarche (t 8 =0·46) but did advance the age at first ovulation in Igf compared with Con females (Table 1 ; t 8 =2·81; power=0·61). Consequently, the interval between menarche and first ovulation was significantly shorter in Igf females (t 8 =2·85; power=0·59). Although the Con females had fewer ovulations in the 12 months following menarche, the difference was not significant (t 8 =1·11). However, the percentage of these cycles with normal luteal phase progesterone secretion was greater in Igf females (t 8 =1·72, one-tailed). Finally, body weights at menarche and first ovulation were similar in Con and Igf females (t 8 =0·74, t 8 =0·59 respectively) as was the average monthly gain in weight (t 8 =0·31).
Using only the data from females having normal luteal phase progesterone concentrations, analysis of serum gonadal hormone concentrations at first ovulation (Fig. 4) revealed that levels of estradiol varied significantly throughout the cycle (F 1,6 =10·30), with higher concentrations observed in Igf compared with Con females during the luteal phase. Serum estradiol concentrations were similar in both groups during the follicular phase. This difference in luteal phase estradiol concentration was also observed during the second ovulation, with significantly higher levels in Igf (415 51 pmol/l) compared with Con females (236 23 pmol/l). In contrast, serum progesterone was similar in the two groups throughout the first ovulatory cycle (F 3, 24 =2·34). The response of serum LH to NMDA was assessed in all subjects prior to menarche (20 months of age), 2 to 3 months post-menarche, and during either their third ovulation or approximately 50 days after their first ovulation. Importantly, the response to NMDA increased with advancing age in all females ( Fig. 5 ; F 2,16 =5·25; power=0·75). The difference between Igf and Con females in response to NMDA was evident during the post-menarchial and post-ovulatory assessments (F 1,8 = 7·07; power=0·65). Furthermore, the response to the second NMDA injection within each assessment also varied with age and was different between the Con and Igf females (F 4,32 =2·86, power=0·71): during the premenarche assessment, both the Con and Igf females responded to the first but not the second NMDA treatment. In contrast, at the post-menarche and postovulation assessments both groups responded to each NMDA treatment but the increase in serum LH was significantly greater in Igf compared with Con females.
Changes in serum LH following treatment with the LHRH analog, Lupron, were similar in Con and Igf females (Fig. 6) . Although baseline concentrations of serum LH were significantly higher in Igf compared with Con females (F 1,8 =5·09, power=0·50), the increase in serum LH following Lupron was similar in the two groups (F 8,64 =<1·00). Serum LH peaked at +3 h following the administration of the analog, returning to pre-treatment concentrations by 9-12 h in both groups of animals.
Discussion
The results of the present study indicate that the experimental elevation of peripheral concentrations of IGF-I has no effect on the timing of menarche but advances the age of first ovulation in female rhesus monkeys. This acceleration was associated with an increased responsiveness of LH secretion to NMDA stimulation. In contrast, the sensitivity of the pituitary to LHRH stimulation was not affected by IGF-I treatment. Furthermore, females receiving IGF-I had a greater incidence of normal luteal phase ovulations, defined by the pattern of serum progesterone, in the 12 months following menarche than did untreated females. In addition, luteal phase estradiol concentrations in these normal ovulatory cycles were consistently higher in IGF-I-treated females compared with untreated animals.
The significantly shorter interval between menarche and first ovulation, resulting in an earlier age at first ovulation, suggests that IGF-I affects those mechanisms regulating LHRH and LH secretion during the final stages of puberty. This hypothesis is supported by the observation that IGF-I enhanced the response of serum LH to NMDA stimulation following menarche but not before. These data Figure 5 Mean ( S.E.M.) serum concentrations of LH in response to the administration of NMDA at three developmental stages in untreated control females (Con; n=6) and females receiving a constant, s.c. infusion of IGF-I (Igf; n=4). NMDA (5 mg/kg, i.v.) was administered at time 0 and +60 min (indicated by the arrows). *P<0·05 Igf compared with Con at the 0 time point. Other significant differences between Igf and Con are illustrated by the probability brackets. complement earlier studies in monkeys which found that thrice weekly GH injections advance first ovulation but not menarche while the long-term administration of a somatostatin analog, which decreases endogenous GH and IGF-I secretion, delays first ovulation (Wilson & Tanner 1994) . In addition, IGF-I diminishes the hypersensitivity to estradiol negative feedback inhibition of LH secretion in steroid-treated, ovariectomized monkeys (Wilson 1995) , a characteristic of late adolescence in monkeys (Rapisarda et al. 1983 , Wilson 1995 . Although IGF-I increases LH secretion in peri-pubertal, intact rats (Hiney et al. 1996) , studies have not examined specifically how IGF-I may modify gonadal steroid negative feedback at first ovulation in this species. However, GH deficiency enhances testosterone negative feedback inhibition of LH secretion in adult mice, an effect reversed by the administration of GH and the resulting increase in IGF-I (Chandrashekar & Bartke 1993) . Taken together, these data suggest that the post-menarchial increase in GH-dependent IGF-I concentrations sets the tempo for the later stages of puberty, determining the occurrence of first ovulation in monkeys.
In contrast to the results obtained in the present study, attempts to evaluate the role of IGF-I on the completion of puberty in rats have produced negative results. Vaginal opening was delayed by several days when serum IGF-I was suppressed to >85% of normal females but was unaffected when serum IGF-I concentrations were, on the average, 50 to 80% lower than those of controls (Gruaz et al. 1994) . In a study similar to the present analysis, subcutaneous infusion of IGF-I to normal rats did not advance the age at vaginal opening, despite an elevation in serum IGF-I greater than 96% of that of untreated animals (Gruaz et al. 1997) . Serum IGFBP-3 levels were also increased by this IGF-I infusion but the ratio of IGF-I to IGFBP-3 was similar to that of untreated control rats, regardless of the IGF-I dose used. In the present study, IGF-I infusion to juvenile monkeys also increased serum IGFBP-3. However, unlike the data from rodents, this increase was not proportional to the elevation in serum IGF-I as the ratio of IGF-I to IGFBP-3 was consistently higher in treated compared with untreated animals. A similar increase in the IGF-I to IGFBP-3 ratio is also observed in IGF-I-treated ovariectomized juvenile females (Wilson 1997) . Although this ratio of IGF-I to IGFBP-3 increased developmentally in control females, the ratio in IGF-I-treated females was significantly greater throughout maturation and did not change. Available data suggest that IGFBP-3 acts to increase the bioavailability of IGF-I by slowing degradation (Froesch et al. 1994) . Indeed, IGF-I therapy to children with GH receptor deficiency produces more growth if IGFBP-3 concentrations do not increase proportionately to the elevation in IGF-I (Guevara- Aguirre et al. 1995 , Ranke et al. 1995 . In order to reconcile the differences between the present study and that in rodents on the effects of IGF-I on the completion of puberty (Gruaz et al. 1997) , more data are needed evaluating how IGFBP-3 affects IGF-I-IGF receptor interactions.
Acute administration of NMDA provided data on the developmental increase in activity of LHRH neurons (Brann 1995) . Indeed, the activation of glutamate receptors has been implicated as a possible mechanism regulating the development of LHRH release (Plant et al. 1989 , Urbanski & Ojeda 1990 and NMDA induces LH secretion in monkeys via activation of LHRH neurons and not through any direct action on the pituitary (Gay & Plant 1987 , Plant et al. 1989 . However, the ability of NMDA to induce an immediate release of LH is dependent upon previous LHRH stimulation of the pituitary and the up-regulation of LHRH receptors (Gay & Plant 1987) . Since glutamate receptors are not found on LHRH neurons but are co-localized with LHRH neurons throughout the mediobasal hypothalamus in the monkey (Goldsmith et al. 1994) , the stimulation of LHRH release by NMDA results from a general excitation of interneuronal circuits near the median eminence (Plant et al. 1989 , Abbud & Smith 1995 . Given these assumptions, we hypothesized that, if IGF-I was having an effect on LHRH neurons, a greater increase in serum LH would be observed following NMDA administration in IGF-Itreated monkeys. The observation that serum LH was increased in IGF-I-treated monkeys following menarche supports this hypothesis and suggests that the premature elevation in IGF-I accelerated the activation of LHRH neurons which eventually led to an earlier age at first ovulation. In support of the hypothesis that IGF-I either directly or indirectly stimulates LHRH neurons, IGF-I induces LHRH release from the rat median eminence in vitro (Hiney et al. 1991) and the immunoneutralization Figure 6 Mean ( S.E.M.) serum concentrations of LH in response to the administration of an LHRH agonist in untreated control females (Con; n=6) and females receiving a constant, s.c. infusion with IGF-I (Igf; n=4). The LHRH agonist (Lupron; 14 g/kg, s.c.) was administered at time 0. Significant differences between Igf and Con are illustrated by the probability bracket.
of LHRH blocks the IGF-I-induced increase in serum LH in juvenile and peripubertal rats in vivo (Hiney et al. 1996) . In contrast, IGF-I inhibits LHRH-stimulated release from hypothalamic explants of peripubertal rats in a dosedependent manner (Bourguignon et al. 1993) . However, since these explants included the arcuate and ventromedial nuclei as well as the median eminence, these contrasting effects of IGF-I on LHRH release may be the result of IGF-I stimulation of different neuronal sub-populations. Only additional studies can reconcile these differences.
IGF-I treatment did not affect the response of the pituitary to stimulation by a long-acting LHRH agonist. However, other studies have shown that IGF-I increases LHRH-stimulated release of LH from pituitary cell cultures (Soldani et al. 1994) . Since pituitary responsiveness to LHRH is primarily regulated by previous LHRH exposure and the up-regulation of LHRH receptors (Wildt et al. 1981) , any effects of IGF-I on pituitary responsiveness could be attributed to the increased LHRH activity due to IGF-I. In addition to these hypothalamic-pituitary effects, IGF-I can increase the ovarian response to gonadotropin stimulation (see Giudice 1992 for a review). The adolescent monkeys treated with IGF-I in the present study exhibited higher luteal phase estradiol levels at the first and second ovulations. These data complement an earlier report in monkeys that a somatostatin analog reduces serum estradiol concentrations during the luteal phase, even in the presence of normal serum progesterone concentrations (Wilson & Tanner 1994) . Consequently, it is not surprising that the augmentation of LH secretion and ovarian responsiveness by IGF-I is associated with a greater proportion of normal luteal phase cycles and suggests that the hypothalamic-pituitary effects of IGF-I may facilitate fertility in developing monkeys (Wilson & Tanner 1994) .
If IGF-I facilitates LH secretion during the final stages of puberty, it must be shown to affect those mechanisms that mediate estradiol negative feedback inhibition prior to first ovulation. However, those neuroendocrine mechanisms themselves are still undefined. In adult animals, gonadal steroids inhibit LH secretion by decreasing the activity of neurons in the mediobasal hypothalamus (O'Bryne et al. 1993) , resulting in a decrease in LHRH biosynthesis (Toranzo et al. 1989 ) and release (Karsch et al. 1987) . Since LHRH neurons do not contain estrogen receptors, these inhibitory effects of estradiol on LHRH biosynthesis and release are complex and probably involve an interneuronal pathway (Herbison et al. 1995 , Sullivan et al. 1995 , possibly the activation of the inhibitory neurotransmitter -aminobutyric acid (GABA) in discrete hypothalamic neurons (Herbison et al. 1991 , McRee & Meyer 1993 . The expression of estrogen receptors on GABAergic and glutamate neurons increases developmentally in female monkeys (Thind & Goldsmith 1997) . Furthermore, GABA concentrations in the stalk median eminence decrease from prepuberty in female monkeys and the ability of GABA antagonists to stimulate LHRH release is developmentally related to endogenous GABA concentrations (Mitsushima et al. 1994) . Since direct synaptic interactions between GABA and LHRH neurons have not been identified in monkeys, the effects are thought to be mediated through interneuron circuits and probably involve reciprocal interactions between GABAglutamate (Thind & Goldsmith 1995) and glutamate-LHRH neurons (Goldsmith et al. 1994) . Consequently, the adolescent hypersensitivity to estradiol negative feedback suppression of LH secretion may be the result of an increased GABAergic inhibition of glutamate receptor excitation of LHRH neurons. Although the specific hypothalamic distribution of IGF-I receptors has yet to be described in primates, IGF-I receptors in rats are found in the median eminence (Lesniak et al. 1988 , Werther et al. 1989 , Aguado et al. 1993 and IGF-I receptor mRNA in this region increases prior to first proestrus in rats (Hiney et al. 1996) . Co-localization and functional analysis studies of neurons containing IGF-I receptors and those immunoreactive for GABA and/or glutamate may help determine whether IGF-I diminishes estradiol-induced activation of GABAergic inhibition of glutamate neurons.
In addition to these effects, IGF-I may affect developmental changes in LHRH by a glial-mediated mechanism. Glial cells in the median eminence contain estrogen receptors (Langub & Watson 1992 ) and the degree of glial apposition to LHRH neurons is decreased by estradiol treatment in adults (Witkin et al. 1991) and decreases developmentally in monkeys . Glialderived transforming growth factor alpha (TGF-), acting through the epidermal growth factor receptor (EGF-r) on astrocytes stimulates LHRH secretion (Ma et al. 1997 ) and the expression of the mRNA for TGF- (Ma et al. 1992) and the EGF-r (Ma et al. 1994a) in the medial basal hypothalamus increases developmentally in rats and following menarche in monkeys (Ma et al. 1994b) . Although the factors responsible for these changes are not known, neurotropic effects of IGF-I may be involved. Glial cells contain IGF-I receptors (Garcia-Segura et al. 1996) and estradiol increases the uptake of IGF-I by glial cells in the mediobasal hypothalamus of developing rats (Duenas et al. 1994) . Finally, IGF-I acting through the IGF receptor has been shown to synergize with EGF to increase growth of astroglia cells in vitro (Han et al. 1992) . Consequently, IGF-I may augment the developmental increase in LHRH via the maturation of TGF--EGF-r system. In this regard, the decrease in adolescent hypersensitivity to estradiol negative feedback by IGF-I would be attributed to the initiation of a stimulatory input to LHRH neurons. These speculations await empirical verification.
The significant acceleration in the age at first ovulation achieved by the premature elevation in serum IGF-I was modest, as was the delay following treatment with the somatostatin analog (Wilson & Tanner 1994) . In another study, the advance in first ovulation in monkeys following the chronic exposure of LHRH neurons to catecholamines and neuropeptide Y-producing tissue (Gore et al. 1996) was greater but considerably more variable than the effect produced in the present study. These results underscore the notion that the development of LHRH secretory function is controlled by multiple convergent synaptic inputs and that the simple manipulation of one such system can produce a modest effect on the tempo of puberty. However, manipulations of these systems will lead to a better understanding of what factors regulate LHRH activity and, consequently, fertility. Finally, it was unfortunate and unforeseen that the sample size for the IGF-I-treated group in the present study was reduced by 33% due to the inefficacy of the IGF-I treatment. Preliminary analysis of these data indicate that this was due to a deficit in serum IGFBP-3 (M E Wilson, unpublished observations). This reduction in sample size certainly reduced the power of the statistical tests evaluating the group differences. A more robust analysis will lend further support to the notion that the developmental increases in IGF-I are important for the attainment of adult reproductive function.
